ARCTIC BIOSCIENCE Aktie

 

12-month readout of the HeROPA phase 2b clinical trial shows potential through key secondary endpoint PGA 0/1, where the per protocol population approaches significance (p = 0.07) after one year of treatment. Relevant subgroups show statistical significance (p < 0.05). Importantly, HRO350 was well tolerated throughout the study, with no safety concerns or drug-related serious adverse events reported. While the primary endpoint (PASI50 at 26 weeks) in the 52-week placebo-controlled study was not met due to an unexpectedly high placebo response, the overall data support the potential of...

The Annual General Meeting of Arctic Bioscience AS was held Monday 26 May 2025 at 11:00 (CET). All the items on the agenda were addressed and approved. Attached is the minutes of the Annual General Meeting. Changes to the Board of Directors: The General Meeting approved the change in the Board of Directors in accordance with the board's proposal, thus the Board of Directors will consist of the following people: · Harald Nordal (chairperson) · Jan Endre Vartdal · Tore A. F. Tønseth · Marita Holstad · Olav Sindre Kriken This information is subject to the disclosure...

Highlights Q1 2025: · Encouraging top-line results from the HeROPA clinical study announced in April · New long-term funding of NOK 30 million secured in January 2025 · Sales development in nutraceuticals according to budget for Q1 2025 with positive outlook · Implemented cost-reducing initiatives are effective and visible in Q1 2025 In April 2025 Arctic Bioscience announced encouraging top-line results from the HeROPA clinical study after 52 weeks of patient treatment. PGA 0/1, a measure indicating clear or almost clear skin, was a key secondary endpoint in this trial. A...

Reference is made to the stock exchange release published by Arctic Bioscience 8th May 2025 regarding Board approval of share capital increase related to the exercise of debt conversion rights and corresponding issuance of new shares in Arctic Bioscience. The share capital increase has now been registered with the Norwegian Register of Business Enterprises. As a result, the new share capital of Arctic Bioscience has increased from NOK 2 668 934 to NOK 2 685 934, divided into 26 859 340 shares, each having a nominal value of NOK 0,10. This information is subject to the disclosure...

Arctic Bioscience AS' Annual General Meeting will be held Monday 26 May 2025 at 11:00 (CET), as a digital meeting. Shareholders are encouraged to cast their votes in advance of the General Meeting or grant the Chair of the Board a proxy, with or without voting instructions. The deadline for registration of attendance, advance votes, proxy or instructions is 22 May 2025 at 16:00 (CET). For attendance at the live event, please follow the instructions in the notice. For further information, see the attached Notice of the Annual General Meeting, which can also be accessed from the company'...

Reference is made to the stock exchange release published by Arctic Bioscience 28th April 2025 regarding exercise of right to convert debt and corresponding issuance of new shares in Arctic Bioscience. On 8 May 2025, the Board of Arctic Bioscience, on the basis of a board authorization granted by the Company's General Meeting on 26[th] April 2024, resolved to increase the share capital from NOK 2 668 934 to NOK 2 685 934 by issuance of 170 000 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 3 per share, including a share premium of NOK 2,90 per share....

Arctic Bioscience has today released its Annual Report 2024, including the Board of Directors report and financial statements. The report and annual accounts were approved by the Board of Directors after close of business on 6[th] of May 2025. On 27 February 2025 Arctic Bioscience reported preliminary and unaudited key results for the fourth quarter and full year 2024. Today's audited accounts include adjustments to gross profit and gross margin due to extraordinary cost provisions of NOK 2,34 million in relation to recall of goods sold to business partners in Q4 2024. The recall issue arose...

With reference to the stock exchange notice of 13[th] of January 2025 regarding new financing via a convertible loan. An investor, which participated in the investor consortium contributing to the convertible loan of total NOK 15 million, has exercised his right to convert the outstanding debt into shares. Debt that will be converted is NOK 510 000. The conversion amount includes accrued interest. The conversion price is set at NOK 3,00 per share based on the received conversion notice. The Board of Directors will issue the shares, pursuant to authorization granted by the Company's General...

The HeROPA phase 2b study in mild-to-moderate psoriasis show encouraging results on key secondary endpoint with increasing durable efficacy up to week 52. Data analyses are ongoing for the full Clinical Study Report. The company will hold a presentation with the full set of data from the study when the Clinical Study Report is ready in June, including statistical significance levels for all datapoints and relevant sub-analyses. Among patients who completed 52 weeks of treatment: · More patients treated with HRO350 achieved “clear” or “almost clear” skin (PGA 0/1) indicating minimal...

All patients have completed 1 year of treatment and the HeROPA phase 2b clinical trial on HRO350 in mild-to-moderate psoriasis is completed. Top-line results were planned to be announced by end of Q1 2025, however cleaning of the comprehensive dataset from more than 500 patients for 1 year of treatment is taking more time than anticipated. The top-line data are currently being cleaned and quality controlled. Top-line results are expected to be published within 2-3 weeks. Analyses on all endpoints will then be presented in the full clinical study report in May this year. This information...

Highlights Q4 2024: · Arctic Bioscience is now funded to cash positive through a NOK 30 million loan facility · Strong \~\30% growth in sales revenues in 2024 and prospects of continued strong growth · Higher prices and product mix of goods sold results in increase of gross margin · Psoriasis drug candidate HRO350 on track for 12 months readout end of Q1 2025 Arctic Bioscience had a strong ending to 2024 with highest ever quarterly sales of the company's nutraceutical products. In Q4 2024 total sales amounted to NOK 15,6 million, a significant increase compared to the same...

With reference to the stock exchange notice of 13[th] of January 2025 regarding new financing via a convertible loan. A group of investors, which participated in the investor consortium contributing to the convertible loan of total NOK 15 million, has exercised their right to convert the outstanding debt into shares. Debt that will be converted amount to NOK 3 million. The conversion price is set at a range of NOK 2,24 to NOK 2,29 per share based on the received conversion notices. The Board of Directors will issue the shares, pursuant to authorization granted by the Company's General...

The sale of ROMEGA®️ products in the Chinese market has grown fast the last 3 years and we see significant growth potential. To accelerate the positive business development, Arctic Bioscience and Kotler Investment Ltd. have signed a term sheet to establish a joint venture operation to commonly develop the Chinese and Southeast Asian markets together to truly realize the business potential. China is the 3[rd] largest regional Omega-3 market in the world after USA and Europe with a market size of more than USD 10 billion (finished products), where dietary supplements alone is about 10%. The...

Reference is made to the stock exchange release from earlier today, 13[th] January 2025, regarding new funding, including a convertible loan facility of NOK 15 million. The following primary insiders, or closely related companies to primary insiders, are a part of the total investor consortium: · Ronja Capital Investment AS, a company closely related to Board Member Tore Tønseth, NOK 3,0 million · Vartdal Holding AS, a company closely related to Board Member Jan Endre Vartdal, NOK 1,0 million · Brødrene Vartdal AS, a company closely related to Board Member Jan Endre Vartdal, NOK 1,...

· Arctic Bioscience is now funded through a NOK 30 million loan facility. · Strong 30% y/y growth in sales revenues in 2024 and prospects of continued strong growth in coming years. · Psoriasis drug candidate HRO350 on track for 12 months readout end of Q1. Reference is made to the stock exchange notice 29[th] October 2024 on Q3 2024 Operational update. The Company announced working on various financing opportunities, where a liquidity contribution of around NOK 30 million was estimated to bring the Company into a positive cash flow position. New funding of NOK 30 million is now...

An Extraordinary General Meeting in Arctic Bioscience AS was held Tuesday 19 November 2024 at 10:00 (CET). All the items on the agenda were addressed and approved. Attached is the minutes of the Extraordinary General Meeting. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act....

An Extraordinary General Meeting in Arctic Bioscience AS will be held Tuesday 19 November 2024 at 10:00 (CET), as a digital meeting. The agenda of the meeting is election of a new auditor for the Company. The Company's elected auditor, Contabile, has informed the Board that they do not have the capacity to continue their assignment responsibilities relating to the audit of the Company. Based on a tender process PricewaterhouseCoopers (PWC) is proposed by the Board to be elected as the Company's new auditor. PWC is considered to handle the Company's future plans for development and will offer...

Highlights Q3 2024: · The HeROPA 6-month read-out showed an effect close to the assumed effect level in the high dose active treatment arm, while the placebo rate was unexpectedly high, preventing the achievement of the primary end-point. The HeROPA study is still ongoing and placebo controlled for 52 weeks ending Q1 2025 · Nutra revenues YTD Q3 are NOK 27,8 million (NOK 23,9 million), expecting a growth of 25-30 % end of 2024 compared to 2023 · Asian markets with strong development; expecting 65-70 % growth compared to 2023 · European market also developing well; expecting 45 %...

Christer Valderhaug, CEO at Arctic Bioscience, has today bought 10,000 shares in Arctic Bioscience at an average price of NOK 1,72 per share. Following the transaction, Christer Valderhaug holds 57,630 shares in Arctic Bioscience. Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities Trading Act § 5-12....

Eggesbø Eiendom AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today sold 520,240 shares in Arctic Bioscience at an average price of NOK 2,23 per share. Following the transaction, Eggesbø Eiendom AS holds 0 shares in Arctic Bioscience. Member of the Board at Arctic Bioscience, Per Magne Eggesbø, is the chairman of the board and CEO of Eggesbø Eiendom AS, and owns 21% of the company. Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements...